Adis R&D Profile
- 4 Downloads
KeywordsChronic Obstructive Pulmonary Disease Congestive Heart Failure Adis International Limited Pulmonary Hypertension Pulmonary Artery Pressure
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- 2.Texas biotechnology completes phase I safety trial for oral endothelin antagonist. PR Newswire [online].: Available from: URL: http://www.newspage.com [Accessed 1997 Dec 12]
- 3.Texas Biotechnology Corporation. Texas Biotechnology presents clinical results on its endothelin A receptor antagonist, TBC11251, at AHA sessions [media release]. 1998 Nov 10Google Scholar
- 4.Givertz M, Colucci WS, Gottlieb SS, et al. Acute ET(A) receptor blockade reduces pulmonary vascular resistance in patients with chronic heart failure. Circulation 1998 Oct 27; 98 Suppl.: 578Google Scholar
© Adis International Limited. 1999